A Study Evaluated Efficacy and Safety of CD19/22 Chimeric Antigen Receptor T Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 16 Feb 2024
At a glance
- Drugs Anti CD22 chimeric antigen receptor T cell therapy-Shanghai Unicar-Therapy Bio-medicine Technology (Primary) ; Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary) ; Tislelizumab (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 01 Jan 2024 Results assessing whether CD19/22 CAR-T cell combined with tislelizumab elicit a safe and durable response in R/R B-NHL and may improve the prognosis of those patients, published in the Hematological Oncology
- 14 Dec 2021 Status changed from recruiting to active, no longer recruiting, according to results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition